Montefiore Medical Center (Moses Campus)

The Bronx, NY

Sorting 8 by

Accepting patients

Venetoclax in Combination With ASTX727

Venetoclax in Combination With ASTX727, an All-Oral Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2

Accepting patients

Danvatirsen Plus Venetoclax

A Phase I Study Investigating the Safety & Efficacy of Danvatirsen as Monotherapy Followed by Combination With Venetoclax in Patients With Relapsed/Refractory MDS & AML
  • Antisense Oligonucleotide (ASO)
  • BCL-2 Inhibitor
  • Phase 1

Accepting patients

AK117/Placebo with Azacitidine

A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2 Study of AK117/Placebo in Combination With Azacitidine in Patients With Newly Diagnosed Higher-risk Myelodysplastic Syndromes
  • Monoclonal Antibody
  • CD47
  • Closed Label (Masked)
  • Placebo
  • Randomization
  • Phase 2

Accepting patients

Low Dose Weekly Decitabine/Venetoclax

Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2

Accepting patients

PedAL Screening

Pediatric Acute Leukemia (PedAL) Screening Trial - Developing New Therapies for Relapsed Leukemias
  • Phase 1/2

Accepting patients

MyeloMATCH Master Protocol

Master Screening and Reassessment Protocol (MSRP) for the NCI MyeloMATCH Clinical Trials
  • Genetic Sequencing
  • Phase 2

Accepting patients

Tetrahydrouridine + Decitabine

Phase 1 Study of Oral Tetrahydrouridine-Decitabine to Treat Relapsed or Refractory Myelodysplastic Syndromes
  • Cytidine Deaminase Inhibitor
  • Phase 1

Accepting patients

SX-682

A Phase 1, Open-Label, Dose-Escalation With Expansion Study of SX-682 Alone and in Combination With Oral or Intravenous Decitabine in Subjects With Myelodysplastic Syndrome
  • CXCR1 Inhibitor
  • CXCR2 Inhibitor
  • Phase 1
  • Has results